Medical experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better describe the condition's hormonal and metabolic dimensions.
This shift in terminology is intended to improve the accuracy of diagnosis and the quality of care for millions of women. By moving away from a name that focuses primarily on the ovaries, the new designation highlights the systemic nature of the disorder.
Experts said the previous name did not fully capture the endocrine and metabolic aspects of the condition. The revised name, PMOS, is designed to shift the clinical focus toward a more comprehensive understanding of how the syndrome affects the body's overall endocrine system.
The condition is widespread, affecting women in many countries globally [1]. Data on the scale of the disorder varies by source; some reports indicate that roughly 10% to 13% of women worldwide are affected [1], while other estimates place the number of people living with the condition at approximately 170 million [2].
Advocates for the change said the reframing is necessary because the disorder is one of the most misunderstood medical conditions affecting women. By clarifying that the syndrome is polyendocrine and metabolic, clinicians may be better equipped to treat the diverse symptoms associated with the condition, ranging from insulin resistance to hormonal imbalances, rather than focusing solely on ovarian cysts.
The transition to PMOS is expected to reduce the stigma and confusion associated with the old terminology. It provides a more precise medical framework for patients and providers to navigate treatment plans that address the root metabolic causes of the syndrome [3].
“The new name (PMOS) is intended to improve understanding, diagnosis, and treatment for millions of women.”
The transition from PCOS to PMOS represents a paradigm shift in how the medical community views the disorder, moving it from a localized reproductive issue to a systemic metabolic one. By centering the endocrine and metabolic components in the name, the medical community is signaling that treatment should prioritize holistic hormonal management over the mere presence of ovarian cysts, potentially leading to earlier interventions for associated metabolic risks.
